# US 2024/0255532 A1 · Biomarkers for the Detection of Thrombosis or Coagulation-Related Disorders and Their Applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255532 A1
- Document ID: US20240255532A1
- Status: Published application
- Kind: A1
- Application number: 18/560,680
- Filed: 2022-05-13
- Published: 2024-08-01
- Earliest claimed: 2021-05-14
- Assignees: Yigong Ruisi Fujian Engineering Rescenter Co Ltd.
- Applicants: Yigong Ruisi Fujian Engineering Rescenter Co Ltd.
- Inventors: Zhe Lin
- Web page: https://patentgrep.com/patent/US20240255532A1

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/91085: Transglutaminases; Factor XIIIq (2.3.2.13)
- G01N 2800/224: Haemostasis or coagulation
- G01N 2800/226: Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the technical field of thrombosis and hemostasis-related disease detection technologies, and in particular to a biomarker and an application thereof in thrombotic and coagulation-related disorders detection. The biomarker comprises an activated peptide of Coagulation Factor XIII (FXIIIAP) and/or an A subunit of Coagulation Factor XIII (FXIIIA). The diagnostic kit provided by the present invention comprises a capture antibody and a detection antibody, which is a specific antibody prepared by using FXIIIAP as an antigen. The biomarker of the present invention has a promising application prospect of rapid screening and diagnosis of thrombotic and coagulation-related diseases, including strokes, can significantly improve the sensitivity and specificity of existing diagnostic methods, speculate the thrombus formation timing and extent, and can predict the severity and prognosis of the disease.

## Claims

### Claim 1

A biomarker for detecting thrombotic or coagulation-related disorders, characterized by comprising a blood coagulation factor 13 activation peptide or/and a blood coagulation factor 13 A subunit.

### Claim 2 (depends on 1)

The biomarker for detecting thrombotic or coagulation-related disorders according to claim 1, characterized by comprising a combination of the blood coagulation factor 13 activation peptide and D-dimer.

### Claim 3 (depends on 1)

The biomarker for detecting thrombotic or coagulation-related disorders according to claim 1, characterized in that the coagulation-related diseases include stroke, cerebral venous thrombosis, renal venous thrombosis, venous thrombosis or myocardial infarction.

### Claim 4 (depends on 1)

An application of biomarkers as described in claim 1 in products for detecting thrombotic or coagulation-related disorders and/or assessing therapeutic effects.

### Claim 5 (depends on 4)

The application of biomarkers as described in claim 4 in products for detecting thrombotic or coagulation-related disorders and/or assessing therapeutic effects, characterized in that the products include a reagent kit or a reagent.

### Claim 6 (depends on 1)

A detection kit for detecting thrombosis or coagulation-related diseases, characterized by comprising a capture antibody and/or a detection antibody, which is a specific antibody prepared by using the biomarker described in claim 1 as an antigen.

### Claim 7 (depends on 6)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 6, characterized in that the detection kit is a double-antibody sandwich ELISA detection kit and/or a dry-type immunofluorescence detection kit, including a capture antibody and a detection antibody.

### Claim 8 (depends on 6)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 6, characterized in that the capture antibody and the detection antibody are prepared by using complete sequence or partial sequence of FXIIIAP as an antigen.

### Claim 9 (depends on 8)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 8, characterized in that the partial sequence includes the following sequence or a fragment comprising the following sequence: SETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVV or RTAFGGRRAVPPNN.

### Claim 10 (depends on 7)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 7, characterized in that the capture antibody and the detection antibody are extracted from a FXIIIAP immunized test animal.

### Claim 11 (depends on 2)

The biomarker for detecting thrombotic or coagulation-related disorders according to claim 2, characterized in that the coagulation-related diseases include stroke, cerebral venous thrombosis, renal venous thrombosis, venous thrombosis or myocardial infarction.

### Claim 12 (depends on 6)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 6, characterized in that the biomarkers mentioned include a combination of blood coagulation factor 13 activation peptide and D-dimer.

### Claim 13 (depends on 12)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 12, characterized in that the detection kit is a double-antibody sandwich ELISA detection kit and/or a dry-type immunofluorescence detection kit, including a capture antibody and a detection antibody.

### Claim 14 (depends on 12)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 12, characterized in that the capture antibody and the detection antibody are prepared by using complete sequence or partial sequence of FXIIIAP as an antigen.

### Claim 15 (depends on 14)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 14, characterized in that the partial sequence includes the following sequence or a fragment comprising the following sequence: SETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVV or RTAFGGRRAVPPNN.

### Claim 16 (depends on 13)

The detection kit for detecting thrombotic or coagulation-related disorders according to claim 13, characterized in that the capture antibody and the detection antibody are extracted from a FXIIIAP immunized test animal.
